These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 27132509

  • 1. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
    Ma Y, Yu C, Mohamed EM, Shao H, Wang L, Sundaresan G, Zweit J, Idowu M, Fang X.
    Oncogene; 2016 Nov 24; 35(47):6132-6142. PubMed ID: 27132509
    [Abstract] [Full Text] [Related]

  • 2. Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer.
    Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, Harada T, Matsumoto K, Takayama K, Takamori S, Kage M, Hoshino T, Nakanishi Y, Okamoto I.
    Clin Cancer Res; 2015 Sep 01; 21(17):4014-21. PubMed ID: 26019170
    [Abstract] [Full Text] [Related]

  • 3. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.
    Takezawa K, Okamoto I, Nishio K, Jänne PA, Nakagawa K.
    Clin Cancer Res; 2011 Apr 15; 17(8):2140-8. PubMed ID: 21415216
    [Abstract] [Full Text] [Related]

  • 4. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
    Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim SM, Kim H, Kang HN, Lee JM, Kim SG, Park CW, Chang H, Shim HS, Lee HW, Cho BC.
    J Thorac Oncol; 2017 Mar 15; 12(3):491-500. PubMed ID: 27836576
    [Abstract] [Full Text] [Related]

  • 5. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
    Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z, Zhang C, Chen X, Chen KX, Li J, Chen SH, Christensen J, Mao M, Chan CC.
    J Thorac Oncol; 2014 Mar 15; 9(3):285-94. PubMed ID: 24496003
    [Abstract] [Full Text] [Related]

  • 6. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ.
    Arch Pathol Lab Med; 2012 Jul 15; 136(7):796-803. PubMed ID: 22742552
    [Abstract] [Full Text] [Related]

  • 7. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.
    Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y.
    J Thorac Oncol; 2008 Jan 15; 3(1):13-7. PubMed ID: 18166835
    [Abstract] [Full Text] [Related]

  • 8. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
    Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z.
    Mol Cancer Res; 2009 Sep 15; 7(9):1466-76. PubMed ID: 19737969
    [Abstract] [Full Text] [Related]

  • 9. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
    Kogita A, Togashi Y, Hayashi H, Sogabe S, Terashima M, De Velasco MA, Sakai K, Fujita Y, Tomida S, Takeyama Y, Okuno K, Nakagawa K, Nishio K.
    Int J Oncol; 2014 Oct 15; 45(4):1430-6. PubMed ID: 25096400
    [Abstract] [Full Text] [Related]

  • 10. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
    Oh SJ, Noh KH, Lee YH, Hong SO, Song KH, Lee HJ, Kim S, Kim TM, Jeon JH, Seo JH, Kim DW, Kim TW.
    Oncotarget; 2015 Nov 24; 6(37):40255-67. PubMed ID: 26517679
    [Abstract] [Full Text] [Related]

  • 11. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.
    Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Janne PA, Nakagawa K.
    Br J Cancer; 2012 Feb 14; 106(4):763-7. PubMed ID: 22240786
    [Abstract] [Full Text] [Related]

  • 12. Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset.
    Guo Y, Ma J, Lyu X, Liu H, Wei B, Zhao J, Fu S, Ding L, Zhang J.
    BMC Cancer; 2014 Nov 18; 14():834. PubMed ID: 25407901
    [Abstract] [Full Text] [Related]

  • 13. Blocking the PI3K pathway enhances the efficacy of ALK-targeted therapy in EML4-ALK-positive nonsmall-cell lung cancer.
    Yang L, Li G, Zhao L, Pan F, Qiang J, Han S.
    Tumour Biol; 2014 Oct 18; 35(10):9759-67. PubMed ID: 24972969
    [Abstract] [Full Text] [Related]

  • 14. EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation.
    Li Y, Li Y, Zhang H, Shi R, Zhang Z, Liu H, Chen J.
    BMC Pulm Med; 2021 Jun 06; 21(1):190. PubMed ID: 34090412
    [Abstract] [Full Text] [Related]

  • 15. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.
    Guo F, Liu X, Qing Q, Sang Y, Feng C, Li X, Jiang L, Su P, Wang Y.
    Biochem Biophys Res Commun; 2015 Apr 10; 459(3):398-404. PubMed ID: 25735977
    [Abstract] [Full Text] [Related]

  • 16. INPP4B-mediated tumor resistance is associated with modulation of glucose metabolism via hexokinase 2 regulation in laryngeal cancer cells.
    Min JW, Kim KI, Kim HA, Kim EK, Noh WC, Jeon HB, Cho DH, Oh JS, Park IC, Hwang SG, Kim JS.
    Biochem Biophys Res Commun; 2013 Oct 11; 440(1):137-42. PubMed ID: 24051093
    [Abstract] [Full Text] [Related]

  • 17. Correlation of anaplastic lymphoma kinase overexpression and the EML4-ALK fusion gene in non-small cell lung cancer by immunohistochemical study.
    Chen TD, Chang IC, Liu HP, Wu YC, Wang CL, Chen YT, Chen YR, Huang SF.
    Chang Gung Med J; 2012 Oct 11; 35(4):309-17. PubMed ID: 22913857
    [Abstract] [Full Text] [Related]

  • 18. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW, Lee MS, Lee SE, Song JY, Shin HT, Kim YJ, Oh DY, Jung K, Sung M, Kim M, An S, Han J, Shim YM, Zo JI, Kim J, Park WY, Lee SH, Choi YL.
    J Pathol; 2017 Nov 11; 243(3):307-319. PubMed ID: 28741662
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.
    Li Y, Ye X, Liu J, Zha J, Pei L.
    Neoplasia; 2011 Jan 11; 13(1):1-11. PubMed ID: 21245935
    [Abstract] [Full Text] [Related]

  • 20. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Zhang SS, Nagasaka M, Zhu VW, Ou SI.
    Lung Cancer; 2021 Aug 11; 158():126-136. PubMed ID: 34175504
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.